BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JAB-23E73 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JAB-23E73\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06959615-2145@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06959615)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: A Phase I/IIa Study of JAB-23E73
  in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06959615
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973564-2145@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06973564)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: JAB-23E73 in Adult Participants 
 With Advanced Solid Tumors With KRAS Alteration\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/j
 ab-23e73#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06973564
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640295-2145@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT07640295)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: Study of JAB-23E73 in Combinatio
 n With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Ge
 ne Alterations\nEstimated primary completion: 31 December 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07640295
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
